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Aim: Homocysteine (Hcy) is a sensitive marker of one-carbon metabolism. Higher Hcy levels 
have been associated with global DNA hypomethylation. We investigated the association 
between plasma Hcy and epigenome-wide DNA methylation in leukocytes. Methods: 
Methylation was measured using Illumina 450 k arrays in 2035 individuals from six cohorts. 
Hcy-associated differentially methylated positions and regions were identified using meta-
analysis. Results: Three differentially methylated positions cg21607669 (SLC27A1), 
cg26382848 (AJUBA) and cg10701000 (KCNMA1) at chromosome 19, 14 and 10, 
respectively, were significantly associated with Hcy. In addition, we identified 68 Hcy-
associated differentially methylated regions, the most significant of which was a 1.8-kb 
spanning domain (TNXB/ATF6B) at chromosome 6. Conclusion: We identified novel 
epigenetic loci associated with Hcy levels, of which specific role needs to be further 
validated. 
Homocysteine (Hcy), an intermediate of the one-carbon metabolism, is an independent risk 
factor of diseases like osteoporotic fractures [1] and cardiovascular disorders [2]. In addition, 
Hcy is often used as sensitive marker of folate- and vitamin B12 deficiency. Recent 
intervention trials were not able to show that lowering of plasma Hcy by B-vitamin 
intervention led to a reduction in disease risk such as myocardial infarction [3–5] and 
osteoporotic fractures [6]. Identification of the underlying pathophysiological mechanism of 
Hcy is warranted to understand its role as biomarker of several disease states. 
Hcy is formed by a demethylation reaction from methionine. In the methionine cycle, s-
adenosylmethionine donates its methyl group to the DNA resulting in s-
adenosylhomocysteine (SAH) as a by-product and a potent inhibitor of this methyltransferase 
reaction. SAH is hydrolyzed to Hcy in a reversible manner. Elevated Hcy in a condition 
known as hyperhomocysteinemia (HHcy) is associated to and increased SAH level, which is 
linked to alterations in DNA methylation [7–9]. This is one of the possible mechanisms in 
Hcy-related pathologies and the rational to study the effect of Hcy on genome-wide DNA 
methylation. 
Hcy is a sensitive marker of one-carbon metabolism and will increase when remethylation or 
trans-sulfuration is impaired. Shortage of folate, vitamin B12 or B6 results in elevated Hcy 
levels. Although folate levels are important, we believe that it is not necessary to correct for 
folate in our analysis as Hcy is strongly correlated to folate and belongs to the same pathway. 
This would have canceled out the effect of Hcy itself on DNA methylation. The general 
hypothesis of this study was that Hcy is associated with changes in DNA methylation 
irrespective of the cause. 
Normal circulating Hcy levels range from 8 to 10 μmol/l for women and 10 to 12 μmol/l for 
men [10]. Mild or moderate HHcy is referred to Hcy concentrations between 15 and 
30 μmol/l, whereas intermediate and severe HHcy is referred to Hcy concentrations between 
30–100 and >100 μmol/l, respectively [10–12]. HHcy has been shown to be associated with 
both global- and gene-specific DNA hypomethylation, which was recently reviewed by us 
[14]. In candidate gene studies of animal models, genes whose methylation have shown 
association with Hcy are the hypomethylation of imprinted genes (e.g., IGF2/H19 locus) 
[19,20], cardiac Trp53 [21], leukocytic mTERT promoter [22], brain Nr3c1 exon region [17], 
brain Ppp2r1a [23] and liver 5′-portion of Soat2 [24] and hypermethylation of the aortic 
Nr3c1 promoter [25] and liver Fads2 promoter [26]. In human studies, HHcy has been shown 
to be associated with altered methylation of the RFC1 gene [27]. For patients with vascular 
disorders, HHcy has shown association with hypomethylation of the leukocytic hTERT 
promoter [22], leukocytic SHC1 promoter [28], punch aortic NOS2 proximal promoter [29] 
and hypermethylation of the blood ESR1 promoter [30] and internal mammary artery NOS2 
proximal promoter [29]. For patients with colorectal, esophageal and breast cancer, HHcy has 
shown association with hypermethylation of ESR1 promoter [31] and exon 1 [32], MLH1 
promoter [33], RARB promoter exon [32], BRCA1 and RASSF1 promoter [34]. 
In animal models, HHcy was also shown to associate with global hypomethylation [15–18]. 
Human studies included mostly small-scale studies in renal or vascular patients with HHcy in 
which global DNA hypomethylation was observed [10,13,35]. Most studies showed 
significant associations of Hcy with DNA methylation, however, also null associations have 
been found [36,37]. Hence, the association between Hcy and DNA methylation is complex, 
contradictory and remains to be fully understood. Mild HHcy can occur due to either genetic 
or environmental factors such as low intake of B vitamins. Regardless of the cause, Hcy itself 
is thought to be the most prominent key player in altering DNA methylation patterns and 
associated disease risks. 
In the current manuscript, we explored the association of Hcy in relation to genome-wide 
CpG site level in leukocytes to assess its role in DNA methylation. In this study, we 
performed a meta-analysis in 2035 individuals of six individual cohorts using the high-
resolution Infinium Illumina 450 k BeadChip arrays. 
Materials & methods 
Cohorts 
Six cohorts participated in the analysis, Rotterdam study [38] (n = 700), Leiden Longevity 
study [39] (n = 550), Cohort on Diabetes and Atherosclerosis Maastricht [40] (n = 186), 
MARseille THrombosis Association study [41] (n = 293), Estonian Biobank [42] (n = 96) and 
French-Canadian family study on Factor V Leiden thrombophilia [41] (n = 210). This added 
up to a total sample size of 2035 for the meta-analysis. The ethics review committees 
approved each study at their relevant organizations. Characteristics of each study are provided 
in Table 1 and Supplementary Text 1. 
Table 1. Characteristics of cohorts included in the homocysteine meta-analysis. 
Cohort N Coun
try 
Type 
(pathoph
ysiology) 
Wo
me
n 
(%) 
Hcy
‡ 
(me
dia
n 
[ra
nge
]) 
H
Hc
y 
(
%
) 
Metho
d 
Tot
al 
prec
isio
n 
(C.
V.%
) 
Tim
e 
betw
een 
bloo
d 
colle
ctin
g 
and 
free
zing 
Age 
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Gran 
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 ± SD) 
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(mean ± SD) 
Mono 
(mean
 ± SD) 
Rotterd
am 
Study 
(RS) 
7
0
0 
The 
Nethe
rlands 
Prospecti
ve, 
populatio
n-based 
(mainly 
healthy) 
54.
7 
11.5 
(5.9
–
35.4
) 
19.
4 
LC–
MS/M
S 
5.5 As 
soon 
as 
possi
ble 
59.8 ±
 8.0 
4.2 ± 
1.5 
2.4 ± 0.7 0.4 ± 
0.4 
Leiden 
Longev
ity 
Study 
(LLS) 
5
5
0 
The 
Nethe
rlands 
Prospecti
ve, 
family-
based 
(mainly 
healthy) 
51.
8 
12.2 
(5.3
–
31.6
)† 
18.
2 
Comp
etitive 
immu
noassa
y 
NA As 
soon 
as 
possi
ble 
58.7 ±
 6.6 
4.4 ± 
1.3 
2.0 ± 0.6 0.4 ± 
0.1 
Cohort 
on 
Diabete
s and 
Atheros
clerosis 
Maastri
cht 
(CODA
M) 
1
8
6 
The 
Nethe
rlands 
Prospecti
ve, 
observati
onal 
(mildly 
increased 
DM2/CV
D risk 
factors) 
54.
8 
10.5 
(5.6
–
29.9
) 
11.
3 
LC–
MS/M
S 
Less 
than 
4.0 
Less 
than 
2 h 
65.3 ±
 7.0 
0.3 ± 
0.1 
0.1 ±
 0.1W 
0.3 ±
 0.1X 
0.2 ±
 0.1Y 
0.1 
± 0.
0Z 
0.1 ± 
0.1 
MARse
ille 
Throm
bosis 
Associa
tion 
Study 
(MAR
THA) 
2
9
3 
Franc
e 
Retrospe
ctive 
(patients 
with 
venous 
thromboe
mbolism) 
80.
3 
10.3 
(3.4
–
33.8
) 
10.
2 
Comp
etitive 
immu
noassa
y 
5.0 Less 
than 
2 h 
43.5 ±
 14.3 
4.4 ± 
1.6 
1.9 ± 0.6 0.3 ± 
0.1 
Estonia
n 
Bioban
k 
(EGCU
T) 
9
6 
Eston
ia 
Populatio
n-based 
(mainly 
healthy) 
50.
0 
13.3 
(6.3
–
34.0
) † 
32.
3 
LC 
with 
photo
metric 
detecti
on 
NA No 
freez
ing 
52.4 ±
 23.7 
3.8 ± 
1.3 
2.0 ± 0.7 0.5 ± 
0.2 
French-
Canadi
an 
family 
study 
on F5L 
thromb
ophilia 
2
1
0 
Cana
da 
Pedigree-
based 
(mainly 
healthy; 
probands 
with 
VTE) 
52.
4 
8.3 
(3.7
–
28.2
) 
3.3 Fluore
scence 
polariz
ation 
immu
noassa
y 
5.2 1–
3 h 
39.8 ±
 16.8 
0.6 ± 
0.1 
0.0 ±
 0.0W 
0.2 ±
 0.1X 
0.1 ±
 0.1Y 
0.1 
± 0.
0Z 
0.1 ± 
0.0 
Gran, Lym, Mono (measured cell counts in 109/l). 
WCD8T.XCD4T.YNK.ZB-cell (Houseman-estimated percentage cell counts). 
†Nonfasting.‡Hcy concentrations in μmol/l. C.V.: Coefficient of Variation; 
CVD: Cardiovascular disease; DM2: Diabetes mellitus type 2; F5L: Factor V Leiden; 
Hcy: Homocysteine; HHcy: Hyperhomocysteinemia (Hcy concentrations >15 μmol/l); 
NA: Not available; NK: Natural killer cells; SD: Standard deviation; VTE: Venous 
thromboembolism. 
Hcy measurements 
Total Hcy was measured in ethylenediaminetetraacetic acid plasma. Measurements in 
nonfasting state were performed in the Leiden Longevity study and Estonian Biobank study, 
while rest of the studies measured Hcy in fasting state. Details of each method are depicted in 
Table 1. Since the absolute values of Hcy in all studies were skewed to the right, logarithmic 
transformation of base 10 was used to achieve normal distribution. For a sample to be 
considered as an outlier, an outlier detection strategy [43] was used with four parameters of 
the Hcy log10 transformed data: quartile 1 (Q1), quartile 3 (Q3), interquartile range (IQR) and 
a multiplying factor (M). The lower end outliers (LO) were detected by the formula, LO = Q1 
- (M*IQR), and upper end outliers (UO) were detected using UO = Q3 + (M*IQR). Any value 
less than or equal to LO and greater than or equal to UO was considered as an extreme outlier, 
using the M 3. A logarithmic transformation of base 10 and removal of outliers showed a 
clear improvement toward normal distribution (Supplementary Figure 1). 
DNA methylation assessment 
Genomic DNA was extracted from whole blood and was bisulfite converted. Infinium 
Illumina HumanMethylation 450k BeadChip arrays (Illumina, Inc., CA, USA) were used to 
perform DNA methylation profiling according to the manufacturers’ protocol. This assay 
covers methylation status of a wide range of CpGs at more than 450,000 sites at regions of 
CpG islands, shores and shelves. The sites annotate to various gene regions like promoters, 
enhancers, gene bodies, exons and UTRs [44]. Standard β-values were considered for the 
methylation analysis in all studies. These contain values ranging from 0 to 1, representing the 
percentage of methylation. β-values are calculated from the methylated (m) and unmethylated 
(u) probe intensities using the formula of β = m/(m + u + α), with the default alpha (α) of 100. 
These values were normalized using methods, such as DASEN [45] or SWAN [46]. Details of 
DNA methylation assessment, preprocessing methods and sample and probe quality control 
used by each cohort are provided in Supplementary Text 1 and Supplementary Table 1. 
Differentially methylated positions 
Statistical analysis to identify differentially methylated positions (DMPs) was performed 
using R programming scripts, which were send around to each cohort and run by each cohort 
separately with log10 transformed Hcy as the exposure variable and DNA methylation as an 
outcome. This association analysis was performed using linear-mixed models of the lme4 
package in R. The association model was adjusted for technical covariates and biological 
covariates like age, sex and differential white blood cell counts. Array number and position on 
array were used as technical covariates, and were treated as random effects. For cohorts that 
did not contain measured white blood cell counts, the counts were inferred using the 
Houseman method as implemented in the minfi package [47] (Table 1). 
Association analyses provided summary statistics from each study. A fixed effect meta-
analysis was performed in 2035 individuals of six cohorts using the classical approach of the 
METAL software [48] that combines effect size estimates and standard errors of each study 
summary statistics. Probes with SNPs at single-base extension site were removed to avoid 
confounding and spurious signals. Probes with improper binding were also removed to avoid 
cohybridization with alternate homologous sequences [49]. In addition, we removed probes 
that were present in less than four studies since each cohort had different probe exclusions. 
This resulted in 468,108 probes remaining. The Benjamini–Hochberg (BH) method was used 
to define statistical significance for a false discovery rate (FDR) less than 0.05. The genomic 
inflation factor (λ) was calculated [50] and cohort heterogeneity was considered by taking into 
account the heterogeneity I2 parameter [48]. CpGs for nearby genes were annotated using the 
Genomic Regions Enrichment of Annotations Tool [51]. This assigns extension up to 5-kb 
upstream and 1-kb downstream to a basal regulatory region from its transcription start site and 
a maximum up to 1-Mb extension distance, as defined by UCSC [52]. 
IGF2/H19 locus 
We also looked up for the three differentially methylated regions (DMRs) of IGF2/H19 locus 
at chromosome 11, which were previously related with Hcy [19,20]. The seven 450 k array 
CpGs underlying the three DMRs of this locus were identified using the literature [36,53,54]. 
Multiple testing using the Bonferroni method was applied on these seven CpGs to test for 
their significance with Hcy. 
Enrichment of previously found folate-associated CpGs 
Because Hcy is associated with folate, we additionally focused our analysis on the previously 
found 443 CpGs in cord blood of newborns associated with maternal plasma folate during 
pregnancy [55]. In order to check for their significant enrichment, we compared their p-values 
with the p-values of randomly selected 443 CpGs from the array, using the Fisher’s exact test. 
Differentially methylated regions 
DMRs were identified using the python library of the comb-p software [56]. Absolute p-
values from the meta-analysis of DMP analysis were given as input to combine them [57] 
adjacently at varying distance lags of 50 base pairs (bp) in a sliding-window of 500 bp, in 
order to calculate autocorrelation between them. As weighted according to this 
autocorrelation, each p-value is adjusted according to its adjacent p-values. An FDR 
correction using the BH method is then calculated on these adjusted p-values. A peak-finding 
algorithm then finds enrichment regions on these FDR-corrected adjusted p-values, and using 
Stouffer–Liptak correction as implemented in comb-p [56,58,59], it then assigns new p-values 
to the identified regions using the original absolute p-values from the meta-analysis. Finally, 
these assigned new p-values of the identified regions are multiple tested using the Sidak 
correction [60], where the defined statistical significance for the identified regions was Sidak-
corrected P less than 0.05. The number of tests for a region in the Sidak correction is the total 
bases covered by input probes divided by the region size [56]. 
DMRs: pathway analysis 
For the pathway analysis, we annotated the regions for genes using the Genomic Regions 
Enrichment of Annotations Tool [51]. We used WEB-based GEne SeT AnaLysis Toolkit 
(WebGestalt) [61] online resource for pathway analysis. KEGG database were used for 
enrichment. The BH method in WebGestalt was used to define statistical significance for an 
FDR less than 0.05. 
Results 
Cohort characteristics 
Meta-analysis comprised of six cohorts with a total of 2035 individuals. All individuals were 
of European ancestry. The study design was mainly population based but also included 
cohorts with increased risk of diabetes, cardiovascular disorders and venous 
thromboembolism. Study characteristics for all the participating cohorts are given in Table 1. 
Differentially methylated positions 
Meta-analysis on 468,108 CpGs was done on the summary statistic of the six cohorts 
(Supplementary Figure 2) comprising of 2035 individuals. The p-values of this analysis 
showed a genomic inflation factor of 1.2 (Supplementary Figure 3). Three DMPs (Table 2 & 
Figure 1) were significantly associated with Hcy (FDR < 0.05). All three DMPs showed 1% 
increase in methylation with each unit increase in the 10 logarithmic Hcy value. The DMP 
cg21607669 located near the gene SLC27A1 at chromosome 19 had the lowest p-value of 7.71 
× 10-8 (FDR = 0.04). The two other DMPs were cg26382848 (nearest gene AJUBA) located at 
chromosome 14 with p-value 1.67 × 10-7 (FDR = 0.04) and cg10701000 (nearest gene 
KCNMA1) located at chromosome 10 with p-value 2.38 × 10-7 (FDR = 0.04). These three 
DMPs showed no substantial cohort heterogeneity I2 (I2 < 35). The direction of effects were 
mostly similar between all studies (Figure 2A–C). 
Table 2. Homocysteine-associated differentially methylated positions. 
Rank CpG N Effect Std 
Err 
p-
value 
FDR HetISq Nearby gene (±bp) Chr Bp Location 
1 cg21607669 2035 0.01 0.001 7.71 × 
10-8 
0.036 0 SLC27A1 (+40) 19 17581292 Promoter 
2 cg26382848 2035 0.01 0.001 1.67 × 
10-7 
0.037 31.1 AJUBA (-39) 14 23451889 Promoter 
3 cg10701000 1346 0.01 0.003 2.38 × 
10-7 
0.037 0 KCNMA1 (-
143,626), DLG5 
(+145,258) 
10 79541025 - 
Effect: β-coefficients based on log-transformed Hcy. HetISq: Heterogeneity Iˆ2 parameter. 
Bp: Base pair location based on Illumina annotation. Location: Based on Illumina annotation, 
derived from UCSC. FDR threshold = 0.05. 
bp: Base pair; Chr: Chromosome; FDR: False discovery rate; Hcy: Homocysteine; Std 
Err: Standard error; UCSC: University of California, Santa Cruz. 
 
Figure 1. Manhattan plot showing the association between homocysteine and genome-
wide DNA methylation in 2035 samples, with three significant differentially methylated 
positions at chromosomes 10, 14 and 19, at false discovery rate less than 0.05 (red line). 
Nearest genes for these three DMPs are reported. 
DMP: Differentially methylated position. 
Figure 2. Forest plots showing the association between homocysteine and the 
significant DMPs across cohorts. 
(A) Forest plot showing the association between homocysteine and the first significant DMP 
cg21607669 across the six cohorts. (B) Forest plot showing the association between 
homocysteine and the second significant DMP cg26382848 across the six cohorts. (C) Forest 
plot showing the association between homocysteine and the third significant DMP 
cg10701000 across the three cohorts. 
DMP: Differentially methylated position. 
IGF2/H19 locus 
We did a lookup for CpGs at the three DMRs of the IGF2/H19 gene (DMR0, DMR2, H19-
DMR3) that have been previously studied in humans [36,53,54]. Data from our 450 k arrays 
contained seven CpGs at these DMRs: two at DMR0, four at DMR2 and one at H19-DMR3. 
However, none of the seven CpGs showed an association with Hcy with a Bonferroni cutoff 
of 7.14 × 10-3 (Table 3 & Supplementary Figure 5). 
Table 3. Homocysteine-associated differentially methylated positions at the three IGF2/H19 
differentially methylated regions at chromosome 11. 
DMR CpG N Effect Std Err p-value Bonferroni HetISq Bp 
H19-DMR3 cg22259242 1532 0.0032 0.0048 0.5014 No 8.6 2021243 
DMR2 cg13165070 1849 0.0041 0.011 0.713 No 0 2154113 
DMR2 cg11717189 1753 -0.0079 0.0143 0.5824 No 0 2154132 
DMR2 cg07096953 2035 -0.002 0.0106 0.847 No 0 2154255 
DMR2 cg02613624 2035 0.0084 0.0072 0.2421 No 32.9 2154386 
DMR0 cg00273464 2035 0.024 0.0094 0.0107 No 54.2 2170412 
DMR0 cg17665927 2035 0.0054 0.0098 0.584 No 30.3 2170443 
Effect: β-coefficients based on log transformed Hcy. HetISq: Heterogeneity Iˆ2 parameter. 
Bp: Base pair location based on Illumina annotation. Bonferroni threshold = 7.14 × 10-3. 
bp: Base pair; DMR: Differentially methylated region; Hcy: Homocysteine; Std Err: Standard 
error. 
 
 
Enrichment of previously found folate-associated CpGs 
For the previously found 443 CpGs in cord blood of newborns associated with maternal 
plasma folate during pregnancy [55], we compared their nominal p-values with 443 randomly 
selected CpGs in the array using 100 permutations. Based on our significant threshold (p < 
0.05), 20 of the 443 folate-related CpGs met the threshold as compared with the 32 of the 443 
randomly selected CpGs in the array. Using the Fisher’s exact test, we found no significant 
enrichment (p-value = 0.97) in the folate-related CpGs. 
Differentially methylated regions 
We identified 68 DMRs significant at Sidak P less than 0.05 (Table 4, Figure 3 & 
Supplementary Figure 4). The most significant was the DMR at chromosome 6 (spanning a 
region of 1.8 kb) with a p-value of 4.34 × 10-24 (Sidak-P = 1.12 × 10-21) containing 55 CpGs. 
CpGs within this region were annotated to gene TNXB and ATF6B. Pathway analysis on the 
114 genes annotated to the 68 DMRs showed 14 significant pathways (Table 5). Top five 
pathways were metabolic pathways, folate biosynthesis, glycosaminoglycan biosynthesis – 
heparan sulfate, phagosome and MAPK signaling pathway. Furthermore, results of the GO 
enrichment analysis showed that many biological processes are related to embryogenesis and 
development (Table 6). 
Table 4. Homocysteine-associated differentially methylated regions. 
Rank Chr Start End Bp 
length 
# 
CpGs 
p-value Sidak-P Mean 
effect size 
Annotated genes Location 
1 6 32063394 32065212 1818 55 4.34 × 
10-24 
1.12 × 
10-21 
-0.04 TNXB (-50398), ATF6B 
(+31714) 
- 
2 22 31317764 31318547 783 12 1.28 × 
10-11 
7.67 × 
10-9 
-0.04 MORC2 (+46031), 
OSBP2 (+227363) 
Enhancer 
3 6 32145146 32146780 1634 29 6.53 × 
10-10 
1.87 × 
10-7 
-0.01 AGPAT1 (-1106), RNF5 
(-168) 
Promoter 
4 7 27142100 27142811 711 15 2.70 × 
10-9 
1.78 × 
10-6 
-0.02 HOXA2 (-26) - 
5 15 91473059 91473570 511 9 2.59 × 
10-9 
2.37 × 
10-6 
-0.02 HDDC3 (+2461), 
MAN2A2 (+25895) 
Promoter 
6 22 32598479 32598717 238 4 5.87 × 
10-9 
1.16 × 
10-5 
-0.03 RFPL2 (+866) - 
7 17 48473757 48474100 343 4 1.16 × 
10-8 
1.59 × 
10-5 
-0.02 LRRC59 (+985) - 
8 2 31806352 31806899 547 6 1.94 × 
10-8 
1.66 × 
10-5 
-0.03 XDH (-169045), 
MEMO1 (+429000) 
- 
9 11 45827260 45827696 436 6 1.61 × 
10-8 
1.73 × 
10-5 
-0.01 CRY2 (-41479), 
SLC35C1 (+1521) 
- 
10 2 129659316 129659947 631 6 5.12 × 
10-8 
3.80 × 
10-5 
-0.04 HS6ST1 (-583481) - 
11 15 31515750 31516482 732 9 1.34 × 
10-7 
8.55 × 
10-5 
-0.03 KLF13 (-102942), 
TRPM1 (-62640) 
Enhancer 
12 10 123355268 123356042 774 5 1.62 × 
10-7 
9.81 × 
10-5 
-0.06 FGFR2 (+2262), 
WDR11 (+744968) 
- 
13 2 72079276 72079610 334 6 7.86 × 
10-8 
1.10 × 
10-4 
-0.04 CYP26B1 (+295724), 
DYSF (+385611) 
- 
14 20 3643863 3644193 330 5 8.80 × 
10-8 
1.25 × 
10-4 
-0.02 GFRA4 (+18) - 
Table 4. Homocysteine-associated differentially methylated regions. 
Rank Chr Start End Bp 
length 
# 
CpGs 
p-value Sidak-P Mean 
effect size 
Annotated genes Location 
15 14 106321551 106322430 879 7 2.89 × 
10-7 
1.54 × 
10-4 
0.01 TMEM121 (+329051) - 
16 6 126080132 126080724 592 4 2.57 × 
10-7 
2.03 × 
10-4 
-0.02 NCOA7 (-21879), 
HEY2 (+9702) 
- 
17 3 142666108 142666477 369 4 2.04 × 
10-7 
2.59 × 
10-4 
-0.04 PCOLCE2 (-58248), 
PAQR9 (+15885) 
- 
18 1 242220475 242220926 451 4 3.66 × 
10-7 
3.80 × 
10-4 
-0.04 MAP1LC3C (-58326), 
PLD5 (+467119) 
- 
19 5 54281198 54281734 536 8 5.68 × 
10-7 
4.96 × 
10-4 
-0.02 ESM1 (+25) Enhancer 
20 16 87978839 87979203 364 3 6.93 × 
10-7 
8.91 × 
10-4 
-0.04 BANP (-24603), CA5A 
(-8899) 
- 
21 5 134735544 134735915 371 8 8.01 × 
10-7 
1.01 × 
10-3 
-0.02 H2AFY (-418) - 
22 2 118616155 118616577 422 5 1.08 × 
10-6 
1.20 × 
10-3 
-0.04 INSIG2 (-229684), 
DDX18 (+44140) 
- 
23 16 89689811 89690263 452 3 1.37 × 
10-6 
1.42 × 
10-3 
-0.04 SPATA33 (-34173), 
DPEP1 (+3037) 
- 
24 13 23412250 23412623 373 4 1.22 × 
10-6 
1.53 × 
10-3 
-0.06 SGCG (-342654) - 
25 6 32805398 32805693 295 6 1.21 × 
10-6 
1.91 × 
10-3 
-0.02 TAP2 (+958) Promoter 
26 7 4764845 4765313 468 4 2.01 × 
10-6 
2.01 × 
10-3 
-0.03 AP5Z1 (-50174), 
FOXK1 (+43139) 
Promoter, 
enhancer 
27 13 23310188 23310676 488 6 2.36 × 
10-6 
2.26 × 
10-3 
-0.04 SGCG (-444659) - 
28 8 48744176 48744603 427 5 2.19 × 
10-6 
2.40 × 
10-3 
0.01 CEBPD (-92742), 
PRKDC (+128353) 
- 
29 7 21209338 21209782 444 4 2.38 × 
10-6 
2.51 × 
10-3 
-0.03 SP8 (-383055), SP4 (-
258092) 
Enhancer 
30 8 141359539 141359787 248 4 1.34 × 
10-6 
2.53 × 
10-3 
-0.04 TRAPPC9 (+109015), 
C8orf17 (+416247) 
Enhancer 
31 7 99724112 99724444 332 4 1.99 × 
10-6 
2.80 × 
10-3 
-0.01 MBLAC1 (-39) Promoter 
32 11 396686 397078 392 3 3.42 × 
10-6 
4.07 × 
10-3 
-0.06 PKP3 (+2665), SIGIRR 
(+18094) 
- 
33 20 62367698 62368257 559 8 5.46 × 
10-6 
4.56 × 
10-3 
0.02 SLC2A4RG (-3236), 
LIME1 (-17) 
Promoter 
34 4 15704393 15704845 452 8 4.79 × 
10-6 
4.95 × 
10-3 
-0.01 BST1 (+46) - 
35 15 81426347 81426670 323 9 3.71 × 
10-6 
5.36 × 
10-3 
0.03 MESDC2 (-144290), 
IL16 (-91232) 
- 
36 5 140762229 140762583 354 4 4.62 × 
10-6 
6.09 × 
10-3 
-0.03 PCDHGA7 (-61) - 
37 1 17634543 17634717 174 4 2.33 × 
10-6 
6.25 × 
10-3 
-0.02 PADI4 (-62) - 
38 16 4802600 4802991 391 4 5.69 × 
10-6 
6.79 × 
10-3 
0.01 ZNF500 (+14423), 
NUDT16L1 (+59101) 
- 
39 20 43883307 43883747 440 4 6.81 × 
10-6 
7.22 × 
10-3 
-0.02 SLPI (-322) - 
40 22 25160033 25160407 374 6 8.42 × 
10-6 
1.05 × 
10-2 
-0.03 PIWIL3 (+10463), 
GGT1 (+161052) 
- 
Table 4. Homocysteine-associated differentially methylated regions. 
Rank Chr Start End Bp 
length 
# 
CpGs 
p-value Sidak-P Mean 
effect size 
Annotated genes Location 
41 7 54732478 54732752 274 2 6.94 × 
10-6 
1.18 × 
10-2 
-0.03 SEC61G (+95052), 
VSTM2A (+122597) 
- 
42 7 27187269 27187692 423 9 1.23 × 
10-5 
1.35 × 
10-2 
-0.01 HOXA5 (-4194), 
HOXA6 (-88) 
- 
43 15 42371511 42371968 457 7 1.49 × 
10-5 
1.51 × 
10-2 
-0.02 PLA2G4E (-28352), 
PLA2G4D (+15012) 
Enhancer 
44 2 1480789 1481098 309 3 1.02 × 
10-5 
1.54 × 
10-2 
-0.04 TPO (+63711), PXDN 
(+267334) 
- 
45 2 86038423 86038803 380 4 1.38 × 
10-5 
1.69 × 
10-2 
-0.02 ATOH8 (+57596), 
ST3GAL5 (+77524) 
Enhancer 
46 15 38988533 38988861 328 4 1.23 × 
10-5 
1.74 × 
10-2 
-0.02 THBS1 (-884597), 
RASGRP1 (-131690) 
- 
47 8 55294536 55294883 347 6 1.34 × 
10-5 
1.79 × 
10-2 
-0.01 SOX17 (-75785), 
MRPL15 (+246940) 
Enhancer 
48 22 20009063 20009276 213 2 8.62 × 
10-6 
1.88 × 
10-2 
-0.01 ARVCF (-4839), 
TANGO2 (+539) 
Promoter 
49 11 44327869 44328155 286 2 1.26 × 
10-5 
2.04 × 
10-2 
-0.02 ALX4 (+3704), EXT2 
(+210265) 
- 
50 3 72704324 72704702 378 4 1.71 × 
10-5 
2.09 × 
10-2 
-0.03 RYBP (-208444), SHQ1 
(+193118) 
Enhancer 
51 10 124578209 124578545 336 4 1.60 × 
10-5 
2.21 × 
10-2 
-0.04 CUZD1 (+31932), 
DMBT1 (+258196) 
- 
52 5 66462293 66462663 370 3 1.78 × 
10-5 
2.23 × 
10-2 
-0.03 CD180 (+30149), 
MAST4 (+570289) 
Promoter, 
enhancer 
53 20 43726431 43726766 335 3 1.64 × 
10-5 
2.27 × 
10-2 
-0.03 KCNS1 (+3154), STK4 
(+131484) 
Promoter 
54 10 135092104 135092242 138 2 8.19 × 
10-6 
2.74 × 
10-2 
-0.02 ADAM8 (-1801) - 
55 2 233251770 233252171 401 4 2.72 × 
10-5 
3.13 × 
10-2 
0.02 ALPPL2 (-19582), 
ALPP (+8727) 
Enhancer 
56 7 156400711 156400991 280 4 2.02 × 
10-5 
3.32 × 
10-2 
-0.04 SHH (-795884), 
C7orf13 (+32497) 
- 
57 10 104196206 104196542 336 5 2.44 × 
10-5 
3.34 × 
10-2 
-0.02 CUEDC2 (-3956) - 
58 4 8126221 8126659 438 4 3.31 × 
10-5 
3.47 × 
10-2 
0 AFAP1 (-184787), 
ABLIM2 (+33996) 
- 
59 20 42955472 42955782 310 3 2.47 × 
10-5 
3.66 × 
10-2 
-0.02 FITM2 (-15818), 
R3HDML (-9999) 
- 
60 22 32599511 32599649 138 5 1.13 × 
10-5 
3.77 × 
10-2 
-0.05 RFPL2 (-116) - 
61 6 27185676 27186077 401 4 3.54 × 
10-5 
4.04 × 
10-2 
-0.05 PRSS16 (-29625), 
HIST1H2AH (+71016) 
- 
62 12 133000383 133000831 448 4 4.13 × 
10-5 
4.23 × 
10-2 
0.02 GALNT9 (-310034), 
MUC8 (+50119) 
- 
63 1 146551565 146551745 180 2 1.68 × 
10-5 
4.27 × 
10-2 
-0.02 PRKAB2 (+92468), 
NBPF12 (+177599) 
- 
64 6 28601269 28601520 251 14 2.43 × 
10-5 
4.44 × 
10-2 
-0.03 SCAND3 (-46283), 
TRIM27 (+290371) 
- 
65 7 117854304 117854635 331 3 3.48 × 
10-5 
4.81 × 
10-2 
-0.02 ANKRD7 (-10260), 
NAA38 (+30384) 
Promoter 
66 6 30656499 30656693 194 7 2.06 × 
10-5 
4.86 × 
10-2 
0.01 PPP1R18 (-924) - 
Table 4. Homocysteine-associated differentially methylated regions. 
Rank Chr Start End Bp 
length 
# 
CpGs 
p-value Sidak-P Mean 
effect size 
Annotated genes Location 
67 3 49723947 49724292 345 3 3.75 × 
10-5 
4.96 × 
10-2 
-0.02 RNF123 (-2812), MST1 
(+2366) 
- 
68 16 129230 129563 333 3 3.63 × 
10-5 
4.98 × 
10-2 
0.01 MPG (+1141), NPRL3 
(+59272) 
Promoter 
bp: Base pair; Chr: Chromosome. 
Figure 3. Manhattan plot showing the association between homocysteine and 
genome-wide DNA methylation in 2035 samples, with 68 significant differentially 
methylated regions, at false discovery rate less than 0.05 (red line) of autocorrelation 
adjusted p-values in comb-p. 
Nearest genes for the top five DMRs are reported. 
DMR: Differentially methylated region. 
Table 5. KEGG pathway analysis using WebGestalt tool. 
Pathways Enrichment 
ratio 
rawP adjP Number 
of genes 
Genes 
Metabolism 
Metabolic pathways 4.13 3.60 × 
10-5 
0.0006 12 MAN2A2, GGT1, ALPPL2, 
GALNT9, ALPP, AGPAT1, TPO, 
BST1, ST3GAL5, EXT2, XDH, 
PLA2G4E 
Folate biosynthesis 70.64 0.0004 0.0034 2 ALPPL2, ALPP 
Glycosaminoglycan 
biosynthesis - heparan 
sulfate 
29.89 0.002 0.0113 2 HS6ST1, EXT2 
Arachidonic acid 
metabolism 
13.17 0.0102 0.0217 2 GGT1, PLA2G4E 
Glycerophospholipid 
metabolism 
9.71 0.0182 0.0314 2 PLA2G4E, AGPAT1 
Cellular processes 
Phagosome 7.62 0.0073 0.0207 3 TAP2, SEC61G, THBS1 
Environmental information processing 
MAPK signaling pathway 5.80 0.0052 0.0207 4 FGFR2, RASGRP1, STK4, 
PLA2G4E 
ECM-receptor interaction 9.14 0.0204 0.0314 2 THBS1, TNXB 
Organismal systems 
Fat digestion and absorption 16.89 0.0063 0.0207 2 PLA2G4E, AGPAT1 
Salivary secretion 8.73 0.0222 0.0314 2 DMBT1, BST1 
Fc gamma R-mediated 
phagocytosis 
8.27 0.0246 0.0322 2 PLA2G4D, PLA2G4E 
Pancreatic secretion 7.69 0.0281 0.0341 2 BST1, PLA2G4E 
Genetic information processing 
Table 5. KEGG pathway analysis using WebGestalt tool. 
Pathways Enrichment 
ratio 
rawP adjP Number 
of genes 
Genes 
Protein processing in 
endoplasmic reticulum 
7.06 0.009 0.0217 3 ATF6B, SEC61G, RNF5 
Human diseases 
HCM 9.36 0.0195 0.0314 2 SGCG, PRKAB2 
ECM: Extracellular matrix; HCM: Hypertrophic cardiomyopathy. 
Table 6. GO analysis using WebGestalt tool. 
GO Id Description Enrichment 
Ratio 
rawP adjP No. 
of 
genes 
Genes 
Biological process 
GO:0048568 Embryonic organ 
development 
5.89 8.31 × 
10-7 
0.0009 12 HEY2, HS6ST1, INSIG2, FGFR2, 
ALX4, HOXA2, HOXA5, SHH, TPO, 
HOXA6, SOX17, STK4 
GO:0003002 Regionalization 5.79 2.95 × 
10-6 
0.001 11 CYP26B1, HEY2, FGFR2, ALX4, 
PRKDC, HOXA2, HOXA5, SHH, 
HOXA6, SOX17, SP8 
GO:0007389 Pattern specification 
process 
4.89 2.25 × 
10-6 
0.001 13 CYP26B1, HEY2, FOXK1, FGFR2, 
ALX4, PRKDC, HOXA2, HOXA5, 
SHH, HOXA6, SOX17, SP8, STK4 
GO:0009790 Embryo 
development 
3.25 7.56 × 
10-6 
0.002 18 CYP26B1, INSIG2, FOXK1, 
PRKDC, TPO, EXT2, SP8, HEY2, 
DMBT1, HS6ST1, ALX4, FGFR2, 
HOXA2, HOXA5, SHH, HOXA6, 
SOX17, STK4 
GO:0048705 Skeletal system 
morphogenesis 
7.27 1.42 × 
10-5 
0.003 8 CYP26B1, INSIG2, FGFR2, ALX4, 
HOXA2, HOXA5, HOXA6, THBS1 
GO:0060484 Lung-associated 
mesenchyme 
development 
48.77 2.62 × 
10-5 
0.0046 3 FGFR2, HOXA5, SHH 
GO:0009952 Anterior/posterior 
pattern specification 
6.25 4.17 × 
10-5 
0.0062 8 HEY2, ALX4, PRKDC, HOXA2, 
HOXA5, SHH, HOXA6, SOX17 
GO:0048598 Embryonic 
morphogenesis 
3.94 4.90 × 
10-5 
0.0064 12 CYP26B1, INSIG2, FGFR2, ALX4, 
HOXA2, HOXA5, SHH, HOXA6, 
SOX17, EXT2, SP8, STK4 
GO:0048514 Blood vessel 
morphogenesis 
4.13 6.83 × 
10-5 
0.0076 11 HEY2, HS6ST1, FGFR2, HOXA5, 
SHH, ADAM8, ESM1, SOX17, XDH, 
STK4, THBS1 
GO:0043009 Chordate embryonic 
development 
3.78 7.30 × 
10-5 
0.0076 12 HEY2, HS6ST1, DMBT1, FGFR2, 
ALX4, PRKDC, HOXA2, HOXA5, 
SHH, HOXA6, SOX17, STK4 
GO:0009792 Embryo 
development ending 
in birth or egg 
hatching 
3.74 8.15 × 
10-5 
0.0077 12 HEY2, HS6ST1, DMBT1, FGFR2, 
ALX4, PRKDC, HOXA2, HOXA5, 
SHH, HOXA6, SOX17, STK4 
GO:0060523 Prostate epithelial 
cord elongation 
108.37 0.0001 0.008 2 FGFR2, SHH 
Table 6. GO analysis using WebGestalt tool. 
GO Id Description Enrichment 
Ratio 
rawP adjP No. 
of 
genes 
Genes 
GO:0051150 Regulation of 
smooth muscle cell 
differentiation 
32.51 9.71 × 
10-5 
0.008 3 HEY2, FGFR2, SHH 
GO:0060916 Mesenchymal cell 
proliferation 
involved in lung 
development 
81.28 0.0002 0.0123 2 FGFR2, SHH 
GO:0001568 Blood vessel 
development 
3.63 0.0002 0.0123 11 HEY2, HS6ST1, FGFR2, HOXA5, 
SHH, ADAM8, ESM1, SOX17, XDH, 
STK4, THBS1 
GO:0060737 Prostate gland 
morphogenetic 
growth 
81.28 0.0002 0.0123 2 FGFR2, SHH 
GO:0061031 Endodermal 
digestive tract 
morphogenesis 
81.28 0.0002 0.0123 2 FGFR2, SOX17 
GO:0001944 Vasculature 
development 
3.46 0.0003 0.0165 11 HEY2, HS6ST1, FGFR2, HOXA5, 
SHH, ADAM8, ESM1, SOX17, XDH, 
STK4, THBS1 
GO:0001525 Angiogenesis 4.1 0.0003 0.0165 9 HS6ST1, FGFR2, HOXA5, SHH, 
ADAM8, ESM1, SOX17, STK4, 
THBS1 
GO:0048562 Embryonic organ 
morphogenesis 
5.24 0.0004 0.0199 7 INSIG2, HOXA6, FGFR2, ALX4, 
HOXA2, HOXA5, SHH 
GO:0045165 Cell fate 
commitment 
5.1 0.0004 0.0199 7 CYP26B1, HEY2, FGFR2, SOX17, 
PRKDC, HOXA2, SHH 
GO:0060441 Epithelial tube 
branching involved 
in lung 
morphogenesis 
19.51 0.0005 0.0237 3 FGFR2, HOXA5, SHH 
GO:0048565 Digestive tract 
development 
7.39 0.0006 0.0241 5 FGFR2, SOX17, ALX4, HOXA5, 
SHH 
GO:0001501 Skeletal system 
development 
3.78 0.0006 0.0241 9 CYP26B1, INSIG2, FGFR2, ALX4, 
HOXA2, HOXA5, SHH, HOXA6, 
THBS1 
GO:0048706 Embryonic skeletal 
system development 
7.46 0.0006 0.0241 5 HOXA6, ALX4, HOXA2, HOXA5, 
SHH 
GO:0030855 Epithelial cell 
differentiation 
4.24 0.0006 0.0241 8 HEY2, DMBT1, FGFR2, HOXA5, 
SHH, SOX17, STK4, XDH 
GO:0010467 Gene expression 1.51 0.0008 0.0246 44 BANP, SIGIRR, ATOH8, INSIG2, 
LIME1, SHQ1, ATF6B, SEC61G, 
SLC2A4RG, KLF13, TRIM27, EXT2, 
SP8, THBS1, HEY2, IL16, PADI4, 
GALNT9, H2AFY, PIWIL3, CRY2, 
SOX17, MRPL15, CEBPD, RYBP, 
CYP26B1, FOXK1, ZNF500, 
PRKDC, NAA38, ST3GAL5, SP4, 
CUZD1, MAN2A2, HS6ST1, FGFR2, 
ALX4, HOXA2, HOXA5, SHH, 
NCOA7, HOXA6, ADAM8, XDH 
Table 6. GO analysis using WebGestalt tool. 
GO Id Description Enrichment 
Ratio 
rawP adjP No. 
of 
genes 
Genes 
GO:0060462 Lung lobe 
development 
46.44 0.0008 0.0246 2 FGFR2, SHH 
GO:0060463 Lung lobe 
morphogenesis 
46.44 0.0008 0.0246 2 FGFR2, SHH 
GO:0034766 Negative regulation 
of ion 
transmembrane 
transport 
46.44 0.0008 0.0246 2 TRIM27, THBS1 
GO:0060664 Epithelial cell 
proliferation 
involved in salivary 
gland morphogenesis 
46.44 0.0008 0.0246 2 FGFR2, SHH 
GO:0060349 Bone morphogenesis 9.7 0.0008 0.0246 4 CYP26B1, INSIG2, FGFR2, THBS1 
GO:0055123 Digestive system 
development 
6.89 0.0008 0.0246 5 FGFR2, SOX17, ALX4, HOXA5, 
SHH 
GO:0001570 Vasculogenesis 9.56 0.0008 0.0246 4 HEY2, SOX17, XDH, SHH 
GO:0060439 Trachea 
morphogenesis 
40.64 0.001 0.0268 2 HOXA5, SHH 
GO:2001212 Regulation of 
vasculogenesis 
40.64 0.001 0.0268 2 HEY2, XDH 
GO:0051151 Negative regulation 
of smooth muscle 
cell differentiation 
40.64 0.001 0.0268 2 HEY2, SHH 
GO:0033089 Positive regulation of 
T-cell differentiation 
in thymus 
40.64 0.001 0.0268 2 ADAM8, SHH 
GO:0045647 Negative regulation 
of erythrocyte 
differentiation 
40.64 0.001 0.0268 2 KLF13, HOXA5 
GO:0035108 Limb morphogenesis 6.25 0.0012 0.0291 5 CYP26B1, FGFR2, ALX4, SP8, SHH 
Cellular component 
GO:0031225 Anchored to 
membrane 
6.64 0.0003 0.0158 6 GGT1, DPEP1, ALPPL2, ALPP, 
BST1, GFRA4 
GO:0012505 Endomembrane 
system 
2.16 0.0002 0.0158 24 CYP26B1, MAP1LC3C, INSIG2, 
ATF6B, SEC61G, AGPAT1, 
SLC35C1, TRIM27, ST3GAL5, 
EXT2, CUZD1, PLA2G4D, 
MAN2A2, DMBT1, HS6ST1, 
GALNT9, FITM2, DYSF, TAP2, 
C8orf17, LRRC59, ADAM8, RNF5, 
RASGRP1 
GO:0042589 Zymogen granule 
membrane 
39.84 0.0011 0.0385 2 CUZD1, DMBT1 
GO: Gene ontology. 
 
Discussion 
This is the first large-scale epigenome-wide site-specific collaborative meta-analysis studying 
the relationship between plasma Hcy levels and methylation at a genome-wide level. Our 
results show that plasma Hcy concentrations were associated with three DMPs and 68 DMRs. 
Identification of this relatively low number of DMPs is surprising, given the central role of 
Hcy in the methylation cycle. 
The most significant of the three DMPs, cg21607669 is located at chromosome 19 near the 
promoter region of the gene SLC27A1 (+40 bp downstream). SLC27A1 assists in the transport 
of fatty acids across cell membrane, and its highest levels are found in muscle and adipose 
tissue [62]. Results from a recent meta-analysis demonstrated that omega-3 polyunsaturated 
fatty acid supplementation was associated with Hcy lowering [63]. It was hypothesized that 
the omega-3 fatty acid, docosahexaenoic acid upregulates metabolic enzymes of the one-
carbon pathway like MAT resulting in increased s-adenosylmethionine bioavailability [63]. 
The exact role of hypermethylation of SLC27A1 should be further investigated to understand 
its possible role in the relation between polyunsaturated fatty acids and HHcy. 
The second significant DMP, cg26382848 is located at chromosome 14 near the promoter 
region of the gene AJUBA (-39 bp upstream). AJUBA plays a role in cellular processes such as 
cell migration, proliferation and differentiation [64,65]. It functions as a negative regulator of 
the retinoic signaling [66] and Hippo signaling pathway [67], and is involved in tumors [68]. 
However, the precise role of this gene is less clear and future replication studies are necessary 
to establish the role of this gene in relation to Hcy. 
The third significant DMP, cg10701000 at chromosome 10 annotated to the nearby gene 
KCNMA1 (-143,626 bp upstream). KCNMA1 is a potassium calcium-activated channel and 
has its prominent role in many physiological processes of smooth muscles, hair cells and 
diseases of nervous system and cancer [69]. A recent study has shown that elevated cellular 
Hcy increases the activity of potassium calcium-activated channel in GH3 pituitary cells [70], 
while two other previous studies have reported that Hcy inhibits these channels of artery 
smooth muscle cells [71,72]. Our finding of hypermethylation near the KCNMA1 gene 
supports the involvement of Hcy in potassium calcium-activated channel. 
We specifically studied the IGF2/H19 locus, the most frequently studied locus in relation to 
Hcy levels, and found that none of the CpGs on the array that were annotated to this locus 
showed an association with Hcy. We could therefore not corroborate results from two earlier 
studies that did find a relationship between Hcy levels and methylation at the IGF2/H19 locus 
[19,20]. The reason could be that these studies were performed in HHcy mice models with 
heterogeneous knockout of the CBS gene, fed with high methionine and low folate diet. CBS 
deficiency is an inborn error of metabolism that  leads to Hcy concentrations much higher at 
intermediate to severe levels, as compared with the ones present in our study. Furthermore, in 
human studies of patients with HHcy and uremia, the influence of Hcy on H19 methylation is 
also observed at a concentration of Hcy much higher at intermediate levels, as compared with 
the mild levels present in our study, and the monoallelic expression of H19 is shown to be 
reversed by folate supplementation [10]. Therefore, our results cannot be directly extrapolated 
in other populations where Hcy is higher especially in chronic renal failure and rare diseases 
of metabolism. However, our results are in line with another human study which did not find 
differences in intermediate HHcy patients with CBS deficiency and controls [36]. These 
patients were under Hcy-lowering therapy, which would have prevented the association with 
H19 DMR. Therefore, mildly elevated Hcy levels do not seem to be related to differences in 
methylation of the IGF2/H19 region in circulating leukocytes. Furthermore, focusing our 
analysis on the previously found CpGs in newborns in relation to maternal plasma folate 
during pregnancy, we did not find significant enrichment. We expected some enrichment 
because of the strong association of Hcy with folate. The reason for not finding enrichment 
could be related to the different study design of mother-offspring relationship compared with 
population-based cohorts. 
Regional analysis using the comb-p software identified 68 DMRs significant at Sidak-P less 
than 0.05. The most significant was 1.8-kb DMR located at chromosome 6 spanning 55 CpGs. 
This DMR was annotated to the genes TNXB and ATF6B. TNXB is located within the class III 
region of the major histocompatibility complex [73] that had multiple CpG sites previously 
shown to be hypermethylated in anorexia nervosa patients compared with controls [74,75]. 
Another gene located near this DMR is the ATF6B gene. This gene is involved in the unfolded 
protein response during endoplasmic reticulum stress and has been shown to be activated 
upon Hcy treatment to human endothelial cells [76]. More specifically a putative ATF6-
binding motif was identified, which was shown to be demethylated upon treatment with Hcy, 
which supports our findings of possible involvement of altered methylation of ATF6B in 
relation to HHcy. 
Among the other DMRs, there were a number of interesting regions that had prior studies 
connecting Hcy to the genes annotated near the CpGs. For example, the DMR 
Chr.6:32,145,146–32,146,780 is annotated to the genes AGPAT1 and RNP5. This region was 
previously found associated to serum vitamin B12 in elderly subjects with elevated Hcy in our 
previous study of B-vitamins for the PRevention Of Osteoporotic Fractures (B-PROOF) [77]. 
Other DMRs, Chr.7:27,142,100–27,142,811 and Chr.7:27,187,269–27,187,692 were 
annotated to the HOX genes, which were previously shown to be differentially methylated 
after a 2-year intervention with folic acid and vitamin B12 [77]. Another gene DPEP1 
annotated to the DMR Chr.16:89,689,811–89,690,263, is involved in renal function and 
contains SNPs previously shown to be associated with Hcy [78–80]. Furthermore, gene 
PADI4 of DMR Chr.1:17,634,543–17,634,717 previously showed to citrullinate DNMT3A, 
and therefore interacting with it to control DNA methylation [81]. And lastly, two out of eight 
CpGs of DMR Chr.5:54,281,198–54,281,734 were significantly shown associated with 
maternal plasma folate levels during pregnancy in cord blood [55]. These regions are 
promising to be replicated in future studies. 
DMR analysis is recommended as a part of the analysis pipeline in addition to CpG site 
analysis [82,83]. It has been shown that methylation is regulated in genomic regions, which 
merits the identification of DMRs in addition to single CpGs. Several software packages are 
available to perform DMR analysis, with their own strengths and weaknesses 
(i.e., Bumphunter, DMRcate) [84]. In this paper, we applied comb-p that constructs regions 
based on the autocorrelation between the p-values at varying lags in a sliding window, which 
is a good approach for the unevenly spaced CpGs in the 450 k array [56]. A recent paper has 
shown that comb-p has good sensitivity. However, if the data signal is weak, comb-p has the 
tendency to return false-positives particularly in presence of low effect size [85]. We, 
therefore, decided to check the DMR results of comb-p in the Rotterdam study subset of 700 
individuals, and compare them with the DMR results of another package, DMRcate [84]. Of 
the 49 significant DMRs within the subset of 700 individuals we found using comb-p 
package, we saw an overlap of 60%, with the DMRs found using DMRcate (data not shown). 
Results of comp-b seem valid but further studies are also necessary to validate these findings 
further. 
Pathway analysis on the 114 genes annotated to the 68 DMRs identified pathways related to 
metabolism such as folate biosynthesis, glycosaminoglycan biosynthesis, arachidonic acid 
metabolism and glycerophospholipid metabolism. This could suggest how elevated Hcy can 
affect other important pathways via DNA methylation impairment. Folate pathways contained 
two genes: ALPPL2 and ALPP. An important paralog of these genes, which is ALPL, 
previously showed polymorphisms that were associated with vitamin B6 that suggests its 
possible role in vitamin B6 catabolism [86]. However, these genes need to be further 
replicated because of its low number in the pathway. Results of the GO enrichment analysis 
showed many biological processes related to embryogenesis and development, where Hcy has 
most variedly shown to play a role by previous studies. 
Most of the studies until now investigated this association by measuring DNA methylation at 
a global level. The strength of our study is that the association of mild HHcy with genome-
wide DNA methylation using 450 k arrays was studied. Second, this is the largest epigenome-
wide association study on Hcy including 2035 individuals. 
Limitations of our study are that clinical heterogeneity between cohorts may have prevented 
us of finding additional true significant associations. Cohorts were either population based, or 
cases with venous thromboembolism, or have a mildly increased risk to develop Type 2 
diabetes and/or cardiovascular disease. Hcy concentrations and related mechanisms may vary 
with such different pathophysiologies [87]. Furthermore, Hcy median concentrations were 
generally low in each cohort, with only 10.2–32.3% of individuals in the mild HHcy range 
more than 15 μmol/l (Table 1), which could explain the subtle findings. Second, we 
acknowledge that Hcy levels were measured using different techniques in each study, either in 
fasting or nonfasting state, as well as there were differences in sample collections per cohort. 
However, the methylation analyses were done in each cohort separately, and the results of 
each separate study were then meta-analyzed. Our results are therefore not biased by the 
differences in Hcy measurement methods, state of fasting or sample collection. Nevertheless, 
this heterogeneity across cohorts could have resulted in null findings. Third, we did not 
account for differences in nutritional folate and/or vitamin B12 intake and B-vitamin 
supplementation, or Hcy-related diseases like renal insufficiency that could have confounded 
the results of our study [87]. We also did not account for the genetic background of 
individuals, especially methylenetetrahydrofolate reductase (MTHFR) 677C >T that is 
associated with Hcy [88]. We could have accounted for these confounding factors, but not all 
of these data were available to us. In addition, these confounding factors like folate, vitamin 
B12 and MTHFR 677C >T belong to the same pathway and are highly correlated with Hcy. 
This would have cancelled out the effect of Hcy itself on DNA methylation. We had 
hypothesized that Hcy is associated with DNA methylation regardless of the cause. However, 
adjusting for MTHFR 677C >T in the linear-mixed model analysis in Rotterdam study-III and 
Cohort on Diabetes and Atherosclerosis Maastricht did not change the findings (data not 
shown). Fourth, we did not account for population stratification in the methylation analysis of 
each cohort because all individuals were of European ancestry. But in order to check the 
influence of this, we reran the analysis only in the Rotterdam study by additionally adjusting 
for four genetic principal components (PCs). The results still showed no significant DMPs 
(FDR < 0.05). In addition, the three significant DMPs of meta-analysis showed same direction 
of effects with and without the four genetic PCs correction (Supplementary Figure 6). 
Therefore, adding additional genetic PCs as covariates did not seem necessary and moreover, 
would reduce statistical power. Fifth, Hcy effect could be exclusive to certain other tissues 
like heart, liver and brain. Future studies still need to explore such findings. And lastly, even 
though we included 2035 individuals from all the possible studies to our knowledge who had 
Hcy and DNA methylation data measured at the same time point, statistical power might still 
be low to identify significant DMP signals. As such, replication was not easily tractable, a 
main limitation of our results. 
Conclusion 
Our meta-analysis showed three DMPs at chromosome 19, 14 and 10 with nearby genes of 
SLC27A1 and AJUBA, and 68 DMRs associated with Hcy concentrations. Knowing the 
prominent role of Hcy in donation of methyl groups, we expected to find more DMPs. 
However, DMR analysis does show promising findings, but their role in relation to one-
carbon metabolism needs to be further investigated. 
Summary points 
• Plasma homocysteine is significantly associated with a modest number of 
differentially methylated positions in leukocyte DNA. 
• Sixty-eight differentially methylated regions related to 114 genes were significantly 
associated with plasma homocysteine. These genes were involved in folate 
biosynthesis, glycosaminoglycan biosynthesis, arachidonic acid metabolism and 
glycerophospholipid metabolism. 
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